Genomic Vision
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.7m | 2.4m | 1.2m | 2.5m | 1.4m | 1.6m | 1.6m |
| % growth | (33 %) | 36 % | (48 %) | 101 % | (42 %) | 9 % | 5 % |
| EBITDA | - | 5.0m | (7.0m) | (4.2m) | (4.6m) | (5.0m) | (6.0m) |
| % EBITDA margin | - | 212 % | (571 %) | (169 %) | (321 %) | (319 %) | (367 %) |
| Profit | (9.5m) | (10.0m) | (7.6m) | (5.1m) | (5.7m) | (5.5m) | (7.5m) |
| % profit margin | (548 %) | (424 %) | (620 %) | (206 %) | (399 %) | (354 %) | (459 %) |
| EV / revenue | 8.3x | 8.2x | 0.6x | 4.6x | 28.0x | 6.8x | 2.8x |
| EV / EBITDA | - | 3.9x | -0.1x | -2.7x | -8.7x | -2.1x | -0.8x |
| R&D budget | 6.2m | 4.9m | 1.8m | <1m | <1m | 2.9m | 3.4m |
| R&D % of revenue | 357 % | 209 % | 149 % | 36 % | 12 % | 188 % | 208 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | Spinout | |
$2.4m | Series A | ||
€4.0m | Series B | ||
| N/A | €25.8m Valuation: €66.8m | IPO | |
* | N/A | €1.9m | Post IPO Convertible |
* | N/A | €1.9m | Post IPO Convertible |
* | N/A | €1.9m | Post IPO Convertible |
| Total Funding | €6.2m | ||
Recent News about Genomic Vision
EditGenomic Vision specializes in advanced genome analysis and genetic diagnostics using proprietary molecular combing technology. The company serves clients in the life sciences sector, including research institutions, clinical laboratories, and pharmaceutical companies. Operating in the genomic diagnostics market, Genomic Vision's business model revolves around selling specialized tools and services for DNA analysis. Revenue is generated through the sale of their molecular combing platforms, diagnostic assays, and related services. The company's technology enables the detection of large genomic rearrangements and complex structural variations, providing a new perspective in molecular diagnostics.
Keywords: molecular combing, genome analysis, genetic diagnostics, DNA replication, telomere measurement, structural variations, hereditary diseases, life sciences, genomic rearrangements, proprietary technology.